Pharsight

Apidra Solostar patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6221633 SANOFI AVENTIS US Insulin derivatives having a rapid onset of action
Jun, 2018

(5 years ago)

US7452860 SANOFI AVENTIS US Zinc-free and low-zinc insulin preparations having improved stability
Mar, 2022

(2 years ago)

US7696162 SANOFI AVENTIS US Zinc-free and low-zinc insulin preparations having improved stability
Mar, 2022

(2 years ago)

US6960561 SANOFI AVENTIS US Zinc-free and low-zinc insulin preparations having improved stability
Jan, 2023

(1 year, 3 months ago)

US8603044 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(2 months ago)

US9827379 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(2 months ago)

US9233211 SANOFI AVENTIS US Relating to a pen-type injector
Mar, 2024

(2 months ago)

US9775954 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(2 months ago)

US9610409 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(2 months ago)

US9604008 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(2 months ago)

US9526844 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(2 months ago)

US9408979 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(2 months ago)

US8556864 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Mar, 2024

(2 months ago)

US9011391 SANOFI AVENTIS US Pen-type injector
Mar, 2024

(a month ago)

US8992486 SANOFI AVENTIS US Pen-type injector
Jun, 2024

(a month from now)

US9604009 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(3 months from now)

US9533105 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(3 months from now)

US9623189 SANOFI AVENTIS US Relating to drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(3 months from now)

US9561331 SANOFI AVENTIS US Drive mechanisms suitable for use in drug delivery devices
Aug, 2024

(3 months from now)

US8512297 SANOFI AVENTIS US Pen-type injector
Sep, 2024

(4 months from now)

US8679069 SANOFI AVENTIS US Pen-type injector
Apr, 2025

(11 months from now)

US7918833 SANOFI AVENTIS US Pen-type injector
Sep, 2027

(3 years from now)

US9717852 SANOFI AVENTIS US Cartridge holder and pen-type injector
Apr, 2033

(8 years from now)

Apidra Solostar is owned by Sanofi Aventis Us.

Apidra Solostar contains Insulin Glulisine Recombinant.

Apidra Solostar has a total of 23 drug patents out of which 14 drug patents have expired.

Expired drug patents of Apidra Solostar are:

  • US6221633
  • US7452860
  • US7696162
  • US6960561
  • US8603044
  • US9827379
  • US9233211
  • US9775954
  • US9610409
  • US9604008
  • US9526844
  • US9408979
  • US8556864
  • US9011391

Apidra Solostar was authorised for market use on 16 April, 2004.

Apidra Solostar is available in injectable;subcutaneous dosage forms.

Apidra Solostar can be used as improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve, improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve, method of treating a patient suffering from diabetes mellitus.

The generics of Apidra Solostar are possible to be released after 08 April, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Oct 24, 2011

Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient

Market Authorisation Date: 16 April, 2004

Treatment: Method of treating a patient suffering from diabetes mellitus; Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glyce...

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

APIDRA SOLOSTAR family patents

Family Patents